neers87

Astra-Zeneca Flies to 'Jupiter' on Drug Results

jimmy48

I think you need to read the study before commenting on.

A 130/30 Generic Pharma Trading Strategy

You missed one, AZN purchased Medimmune labs, and recently announced they will be targeting Bio Generics as a part of that unit.

Pharmaceutical Facts Investors Should Know

"'try a million combinations of everything' approach to drug development traditionally followed by big pharma."

Exactly my point! Drug modeling allows this approach to be teased out with significant reductions in time and obviously expense.

As for "Enter Biotech and rational drug design", Agreed!!! And big pharma is well positioned financially as the young limber unencumbered companies will need partners to bring these entities to market. Much like the NIH as mentioned above. Think AZ-MedImmune.


Disclosure: Long AZ

Pharmaceutical Facts Investors Should Know

Pharma has long operated profitably under these premise. The trick these days is to reduce time from discovery to market, extending time on the market with exclusive patent protection. Eliminate candidates as earily in the process as possible for a reduction in cost. New technologies make this possible, drug modeling software is a much larger aspect of R & D. Your article looks at the situation as if it were static. Dynamic changes are in the industry beyound what is mentioned here.